Interleukin-6 and intrapulmonary shunt
- 1Dept of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
- 2CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- 3Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain
- 4Critical Care Service, Hospital Universitario de Getafe, Madrid, Spain
- 5Universidad Europea, Madrid, Spain
- Francisco Perez-Vizcaino (fperez{at}med.ucm.es)
Abstract
Based on animal studies and indirect clinical evidence, it may be speculated that IL-6 has a pathophysiological role in intrapulmonary shunt associated to COVID-19 https://bit.ly/3whQVqd
To the Editor:
We read with interest the article by Kotwica et al. [1] showing the utility of clinical pulse oximetry measurements to quantify shunt and ventilation–perfusion mismatch and their predictive value in severe coronavirus disease 2019 (COVID-19). The authors found that shunt correlated with markers of activated inflammatory response (i.e. C-reactive protein) but not those of activated coagulation (such as D-dimer). Their results reinforce the growing evidence for the role of impaired hypoxic pulmonary vasoconstriction (HPV) as a primary cause for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced hypoxaemia [2].
We would like to draw the attention of readers to a possible pathophysiological role of interleukin (IL)-6 in intrapulmonary shunt associated with SARS-CoV-2-induced acute respiratory distress syndrome that has been overlooked. IL-6 is a fundamental player in the inflammation associated with COVID-19 and the level of this cytokine serves as a biomarker of poor prognosis [3]. Moreover, although controversy remains regarding the population of patients that may benefit from anti-IL-6 therapies in COVID-19, two large randomised clinical trials have shown reduced mortality in patients treated with tocilizumab [4, 5], and seven randomised controlled trials have shown reduced risk of mechanical ventilation [6].
The initial evidence for the involvement of IL-6 in impaired HPV comes from studies in mice and rats. Thus, human recombinant IL-6 inhibited HPV in mice [7]. We also observed that IL-6 inhibited HPV and an antibody against IL-6 prevented the impairment of HPV induced by bacterial endotoxin in isolated rat pulmonary arteries [8]. In addition, several studies have demonstrated a positive impact of tocilizumab on arterial oxygenation in patients with severe COVID-19 [9, 10].
In conclusion, we speculate that IL-6 is involved in the impaired HPV associated with COVID-19. The relationship of intrapulmonary shunt with IL-6 levels and with anti-IL-6 therapies deserves further investigation.
Shareable PDF
Supplementary Material
This one-page PDF can be shared freely online.
Shareable PDF ERJ-01292-2021.Shareable
Footnotes
Conflict of interest: F. Perez-Vizcaino reports fees for lectures from Actelion.
Conflict of interest: L. Moreno has nothing to disclose.
Conflict of interest: J.A. Lorente has nothing to disclose.
- Received May 5, 2021.
- Accepted June 6, 2021.
- Copyright ©The authors 2021.
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org